To: University Hospitals Physicians and Employees
From: Jeffrey Peters, MD
Chief Operating Officer, University Hospitals
Date: July 22, 2016
Jonathan Stamler, MD, has been named President of Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development. He has been a driving force behind the success of Harrington Discovery Institute as its Director since its founding in 2012. 
Today, the Harrington Discovery Institute is widely recognized as a novel model for advancing discovery for societal benefit and provides over $15 million each year in financial and commercialization support to 35 Harrington Scholars across North America and the United Kingdom. Major Institute initiatives include new company creation through collaboration with BioMotiv, a mission-aligned for-profit that has developed and grown relationships with global pharmaceutical companies. The Harrington Discovery Institute has grown its nonprofit operations in collaborations with the State of Ohio through the Ohio Third Frontier, pharmaceutical companies, disease foundations and academic institutions, including the Alzheimer’s Drug Discovery Foundation, the Foundation Fighting Blindness and the University of Oxford in the United Kingdom.
Dr. Stamler’s expanded role will allow him to focus on continued growth of Harrington Discovery Institute and The Harrington Project. Immediate plans call for implementation of Harrington Centers of Excellence, which will serve as hubs of discovery in specific clinical and therapeutic areas, as well as developing new models of revenue creation through alignment of nonprofit and for-profit venture enterprises within The Harrington Project. He will continue to serve as Director, Institute for Transformative Molecular Medicine at UH Case Medical Center and Case Western Reserve University School of Medicine.
Dr. Stamler is an internationally renowned physician-scientist and is recognized for the discovery of protein S-nitrosylation, a universal mechanism for controlling protein function in cells. His insights have impacted understanding of diseases ranging from heart disease to neurological disorders and cancer.
He came to UH in 2010 and holds the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair of Cardiovascular Innovation. He is a Professor of Medicine and Biochemistry at the School of Medicine.
Dr. Stamler earned his medical degree from Mount Sinai School of Medicine in New York and completed his internship, residency and fellowships in cardiovascular and pulmonary medicine at Harvard Medical School and Brigham and Women’s Hospital, Boston. He was on the faculty at Harvard University before spending 16 years at Duke University and the Howard Hughes Medical Institute, Durham, North Carolina.
Dr. Stamler has published nearly 300 original articles and edited two books. He has co-founded seven biotechnology companies and licensed two additional programs to major pharmaceutical companies. He holds more than 125 patents and patent applications, and has been recognized by several awards and prizes, including recognition by the Ewing Marion Kauffman Foundation for being among the “Top Innovators in America” and by the American Heart Association as a “Distinguished Scientist.”
We are entering an exciting new phase in the development of Harrington Discovery Institute under Dr. Stamler’s leadership. Please join me in congratulating Dr. Stamler as we further the Institute’s potential to dramatically impact human health across the globe.